Lawsuits against generic drugmakers have typically been a small but significant slice of the mass tort litigation pie in Philadelphia, but according to attorneys who work in the pharmaceutical arena, that slice has shrunk to nearly nothing.
Although the Philadelphia Complex Litigation Center does not keep track of the number of claims against generic drugmakers, both plaintiffs and defense attorneys said the filings have dropped to almost zero in the past five years, due almost entirely to a U.S. Supreme Court decision.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
